Clinical Trial

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Study acronym: PLATFORM
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2016-02-04; most recent amendment 2025-06-05.
Status change: Recruiting → Active, Not Recruiting 2024-09-02
Trial Details
NCT Number NCT02678182
Lead Sponsor Royal Marsden NHS Foundation Trust
Collaborators: MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Conditions Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
Enrollment 494 participants
Start Date 2015-02
Primary Completion 2025-04-17 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-10